CTLA4 and pneumonitis: Our meta-analysis showed that when combining ipilimumab (CTLA-4 inhibitors) with nivolumab (PD-1 inhibitors), the risk of all-grade pneumonitis (3.47 times), and severe pneumonitis (3.48 times) were higher than nivolumab or ipilimumab alone.